Real-time Estimate
Cboe BZX
11:12:45 21/05/2024 pm IST
5-day change
1st Jan Change
23.58
USD
-0.74%
+15.28%
+10.55%
Presentation Operator MessageOperator (Operator)Good afternoon, ladies and gentlemen, and than...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Xencor, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM
16/05
Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating
10/05
MT
Earnings Flash (XNCR) XENCOR Reports Q1 Revenue $12.8M
10/05
MT
Xencor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
10/05
CI
BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating
16/04
MT
Xencor Names Bart Cornelissen as Chief Financial Officer
09/04
MT
Xencor, Inc. Announces CFO Changes
09/04
CI
Xencor Appoints Bart Cornelissen as Senior Vice President
09/04
CI
Transcript : Xencor, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:15 AM
14/03
Xencor Insider Sold Shares Worth $293,519, According to a Recent SEC Filing
08/03
MT
North American Morning Briefing : Fed's Preferred -2-
29/02
DJ
Wedbush Adjusts Xencor's Price Target to $34 From $36, Keeps Outperform Rating
28/02
MT
Transcript : Xencor, Inc., Q4 2023 Earnings Call, Feb 27, 2024
28/02
Earnings Flash (XNCR) XENCOR Posts Q4 Revenue $44.7M, vs. Street Est of $74.7M
28/02
MT
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
28/02
CI
Xencor Insider Sold Shares Worth $1,048,743, According to a Recent SEC Filing
15/02
MT
Transcript : Xencor, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
11/01
Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy
02/01
CI
Xencor Insider Sold Shares Worth $941,670, According to a Recent SEC Filing
30/12
MT
Xencor, Inc. Enters into an Amended and Restated Collaboration and License Agreement with Genentech, Inc
16/11
CI
RBC Cuts Price Target on Xencor to $32 From $36, Keeps Outperform, Speculative Risk
08/11
MT
Wedbush Trims Xencor's PT to $36 From $37 After Stopping XmAb104 Development, Opting Out of Cost Sharing With Genentech to Co-develop XmAb306; Maintains Outperform Rating
08/11
MT
Transcript : Xencor, Inc., Q3 2023 Earnings Call, Nov 07, 2023
08/11
Earnings Flash (XNCR) XENCOR Reports Q3 Revenue $59.2M, vs. Street Est of $30M
08/11
MT
Xencor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
08/11
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
More about the company
Last Close Price
23.75
USD
Average target price
35.92
USD
Spread / Average Target
+51.23%
Consensus
1st Jan change
Capi.
+10.55% 1.46B +7.52% 115B +12.61% 107B -13.44% 22.31B -3.99% 21.6B -6.38% 18.23B -39.93% 17.62B +6.87% 14.26B +32.73% 12.37B -28.14% 8.28B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1